BiomX Inc. is a pioneering biotech company harnessing the power of microbiomes to develop innovative phage therapies for chronic diseases such as IBD, CRC, and skin conditions.

BiomX Inc. reported better-than-expected earnings for the quarter ending March 31, 2025, with a GAAP EPS of -$0.33, surpassing analysts’ expectations by $0.03.